Vandria announced it has closed a second Series A financing round, bringing total funding to $30.7 million (CHF 28.3 million). According to the company, new investors Hevolution Foundation and Dolby Family Ventures joined the round, which aims to advance its lead candidate, VNA‑318, into clinical trials. The company said VNA‑318 is an oral mitophagy inducer targeting central nervous system (CNS) diseases linked to mitochondrial dysfunction. Vandria claims preclinical data support its potential to clear damaged mitochondria and restore cellular energy balance, offering a new therapeutic approach for age-related neurodegenerative disorders. According to Vandria, proceeds from the financing will fund a first-in-human clinical…
Author: Michael
DeepLife secures $10m to advance AI platform des
Vancouver-based health technology company Prenuvo
Research links hidden visceral fat to abnormal p
Company targets metabolic, immunological and neu
Spain-based fund targets challenges posed by agi
How professional care can integrate personalized
Crypto investor-backed LongGame aims to fund tec
Clinical trial of company’s osteoporosis drug
Hooke London has partnered with Citius Retreats t